42:I[58016,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/5e17b2e37c80a96c.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/53f751967ccc7d59.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/00da439d4db502cc.js","/_next/static/chunks/88bed98e5cd5e639.js"],"ProcessEpisodeButton"] 47:I[45269,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/5e17b2e37c80a96c.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/53f751967ccc7d59.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/00da439d4db502cc.js","/_next/static/chunks/88bed98e5cd5e639.js"],"SignupCTA"] 49:I[56939,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/5e17b2e37c80a96c.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/53f751967ccc7d59.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/00da439d4db502cc.js","/_next/static/chunks/88bed98e5cd5e639.js"],"EpisodeTranscript"] 3c:["$","div",null,{"className":"flex flex-col gap-2 text-sm text-muted-foreground","children":[["$","span",null,{"className":"inline-flex items-center gap-2 bg-secondary/50 px-3 py-1 rounded-full","children":[["$","svg",null,{"className":"w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M8 7V3m8 4V3m-9 8h10M5 21h14a2 2 0 002-2V7a2 2 0 00-2-2H5a2 2 0 00-2 2v12a2 2 0 002 2z"}]}],["$","time",null,{"dateTime":"2025-06-30T05:00:00.000Z","children":"Mon Jun 30 2025"}]]}],null]}] 43:T541,

Join us for an eye-opening exploration of how virtual patient data is revolutionising paediatric clinical trials. In our upcoming episode, we delve into groundbreaking research that addresses one of healthcare's most pressing challenges: the power crisis plaguing paediatric randomised controlled trials.

Discover how digital twins, synthetic patient data, and in silico trials are offering unprecedented solutions to reduce children's exposure to unproven therapies whilst accelerating drug approvals. We'll examine the transformative potential of these technologies in creating personalised treatment options at significantly lower costs, ultimately leading to faster clinical implementation of life-saving interventions.

However, innovation comes with responsibility. Our discussion critically evaluates the ethical and regulatory frameworks necessary to ensure safe, sustainable adoption of virtual patient data in paediatric medicine.

Join our interactive webinar to engage directly with experts and explore how these digital innovations are shaping the future of children's healthcare.

Source: Pammi M, Shah PS, Yang LK, Hagan J, Aghaeepour N, Neu J. Digital twins, synthetic patient data, and in-silico trials: can they empower paediatric clinical trials? Lancet Digit Health. 2025

44:T926,

Digital Twins & Virtual Patients: Revolutionising Paediatric Clinical Trials